NOVO.B.DK

361.5

+1.1%↑

COLO.B.DK

610.8

-0.16%↓

GMAB.DK

1,615.5

+1.22%↑

ZEAL.DK

438.2

+4.01%↑

NOVO.B.DK

361.5

+1.1%↑

COLO.B.DK

610.8

-0.16%↓

GMAB.DK

1,615.5

+1.22%↑

ZEAL.DK

438.2

+4.01%↑

NOVO.B.DK

361.5

+1.1%↑

COLO.B.DK

610.8

-0.16%↓

GMAB.DK

1,615.5

+1.22%↑

ZEAL.DK

438.2

+4.01%↑

NOVO.B.DK

361.5

+1.1%↑

COLO.B.DK

610.8

-0.16%↓

GMAB.DK

1,615.5

+1.22%↑

ZEAL.DK

438.2

+4.01%↑

NOVO.B.DK

361.5

+1.1%↑

COLO.B.DK

610.8

-0.16%↓

GMAB.DK

1,615.5

+1.22%↑

ZEAL.DK

438.2

+4.01%↑

Search

H Lundbeck A-S

Avatud

40.86 0.84

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

39.82

Max

40.94

Põhinäitajad

By Trading Economics

Sissetulek

-186M

966M

Müük

-212M

6B

P/E

Sektori keskmine

11.091

35.724

Aktsiakasum

1.35

Dividenditootlus

2.38

Kasumimarginaal

16.039

Töötajad

5,700

EBITDA

811M

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.38%

3.09%

Turustatistika

By TradingEconomics

Turukapital

3.7B

37B

Eelmine avamishind

40.02

Eelmine sulgemishind

40.86

H Lundbeck A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. aug 2025, 22:51 UTC

Tulu

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27. aug 2025, 23:57 UTC

Tulu

Trip.com Group 1H Rev $4.01B

27. aug 2025, 23:57 UTC

Tulu

Trip.com Group 1H Adj EPS $1.84

27. aug 2025, 23:57 UTC

Tulu

Trip.com Group 1H EPS $1.82

27. aug 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27. aug 2025, 23:39 UTC

Tulu

Correction to Nvidia Earnings Article -- WSJ

27. aug 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. aug 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27. aug 2025, 22:58 UTC

Tulu

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27. aug 2025, 22:57 UTC

Tulu

South32 FY Free Cash Flow $192 Million

27. aug 2025, 22:56 UTC

Tulu

South32 FY Total Capital Expenditure $1.35 Billion

27. aug 2025, 22:56 UTC

Tulu

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27. aug 2025, 22:55 UTC

Tulu

South32 Net Cash $123 Million at June 30

27. aug 2025, 22:54 UTC

Tulu

South32: Focused on Maintaining Strong Operating Momentum

27. aug 2025, 22:53 UTC

Tulu

South32: $144 Million Remains to be Returned to Shareholders Under Program

27. aug 2025, 22:53 UTC

Tulu

South32 Extends Capital Management Program for 12 Months

27. aug 2025, 22:52 UTC

Tulu

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27. aug 2025, 22:51 UTC

Tulu

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27. aug 2025, 22:51 UTC

Tulu

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27. aug 2025, 22:50 UTC

Tulu

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27. aug 2025, 22:50 UTC

Tulu

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27. aug 2025, 22:45 UTC

Tulu

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27. aug 2025, 22:44 UTC

Tulu

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27. aug 2025, 22:44 UTC

Tulu

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27. aug 2025, 22:43 UTC

Tulu

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27. aug 2025, 22:43 UTC

Tulu

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27. aug 2025, 22:42 UTC

Tulu

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27. aug 2025, 22:42 UTC

Tulu

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27. aug 2025, 22:40 UTC

Tulu

Sandfire Resources Net Debt $123 Million at June 30

27. aug 2025, 22:40 UTC

Tulu

Sandfire Resources FY Underlying Ebitda $527.7 Million

Võrdlus sarnastega

Hinnamuutus

H Lundbeck A-S Prognoos

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.